Resistance to Tyrosine Kinase Inhibitors
-
- €119.99
-
- €119.99
Publisher Description
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
More Books Like This
Apoptosis, Cell Signaling, and Human Diseases
2007
Protein Tyrosine Kinases
2007
Frontiers in Clinical Drug Research - Anti-Cancer Agents: Volume 3
2016
Improving the Therapeutic Ratio in Head and Neck Cancer
2019
Combinational Therapy in Triple Negative Breast Cancer
2022
Translational Medicine
2016
More Books by Daniele Focosi
Other Books in This Series
Resistance to Targeted Therapies Against Adult Brain Cancers
2016
TRAIL, Fas Ligand, TNF and TLR3 in Cancer
2017
Resistance to Molecular Therapies for Hepatocellular Carcinoma
2017
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
2018
Resistance to Targeted Therapies in Breast Cancer
2017
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
2018